The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.25
Bid: 16.00
Ask: 16.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.125%)
Open: 16.25
High: 16.25
Low: 16.25
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Tue, 09th Jun 2020 13:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Venture Life Group PLC - Berkshire-based self care products maker - Says order book "significantly ahead" of year prior. Reports solid demand for hand sanitiser gel product. Extends relationship with Alliance Pharma, becoming second manufacturer of Wiltshire-based pharmaceutical firm's Kelo-Cote scar gel products.

----------

Better Capital PCC Ltd - Guernsey-based investment company - To take write-down on valuation of investment in Everest, a British windows and home improvement firm. Better Capital's Fund II has invested GBP3.2 million into creation of Everest 2020, which bought assets of Everest Ltd, including its order pipeline. Pre-packaged administration deal rescued over 400 jobs at Everest and ensures existing orders can be completed.

----------

Plaza Centers NV - Netherlands-based property firm - Says buyer of company's stake in a shopping and entertainment centre in Belgrade will pay firm EUR830,000 to settle purchase. Plaza Centers to increase amount paid to bondholders to EUR500,000 from EUR250,000 at next payment date on July 1.

----------

Altyn PLC - gold miner in Kazakhstan - Says "positive momentum" continuing in second quarter with annualised monthly production run rate of 600,000 tonnes per year achieved in April and May. Altyn adds this represents 60% growth quarter-on-quarter. Altyn explains gold recovery grades also improved and beating budgeted targets. Seeing pick up in interest among investors, so far raised USD3.2 million out of USD10 million maximum in Astana Stock Exchange bond issue.

----------

Ormonde Mining PLC - Spain-focused natural resources - Cost-effective work programme at existing Spanish gold assets being advanced. Continuing to assess prospective projects, with 100 reviewed to date and a handful shortlisted "for further active consideration".

----------

Chaarat Gold Holdings Ltd - Gold miner in Armenia and Kyrgyz Republic - Targets 300,000 ounces per year production from 2026 at Kyzyltash deposit, Kyrgyz Republic. Lays out plans to get there, beginning with updated feasibility study in 2022, project financing in 2023 before construction follows in 2024 and 2025.

----------

Rockfire Resources PLC - Australia-focused gold and copper explorer - Reports results of 3D magnetic imagery at Plateau gold deposit in Lighthouse tenements, Australia. Probe confirms gold target beyond a depth of 600 metres. Field crew now in place to prepare for start of drilling.

----------

Star Phoenix Group Ltd - oilfield services firm in Trinidad - Yet to receive outstanding USD1.5 million payment from LandOcean Energy Services Co Ltd over sale of Range Resources Trinidad Ltd. Agreed deadline for payment was Monday and Star Phoenix has made "numerous attempts" to secure cash. Company now working with legal advisers.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Awarded grant for research with Cardiff University to assess whether its DPD‑207, XF-70 and XF-73 drug compounds can treat fungal infections. Financial terms of partnership not disclosed.

----------

PureTech Health PLC - biotherapeutics firm based in Massachusetts - Reports "positive" data from founding company Vedanta Biosciences Inc's two Phase 1 studies of VE202 candidate for inflammatory bowel disease. Study shows VE202 was "safe and well-tolerated at all doses".

----------

Hutchison China Meditech Ltd - Hong Kong-based biopharmaceutical firm - Enters into agreement with Guangzhou government for planned return of Hutchison's remaining 34 years land-use rights of about 30,000 square meters of unused site. Hutchison will secure USD95 million for the return of the site.

----------

iEnergizer Ltd - Guernsey-based IT services firm - Reports strong performance in six months to March 31, its year end date. Says focus remained on high margin work and revenue set to be in line with market expectations but earnings before interest, taxes, depreciation and amortisation beating forecasts. Reaffirms commitment for progressive dividend policy.

----------

Redcentric PLC - London-based IT services provider - Extends loan facilities until June 30, 2022. Extended loan is a GBP17.5 million revolving credit facility provided by Barclays Bank PLC and National Westminster Bank PLC.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2018 13:09

Destiny Pharma Biofilm Project With Southampton Uni Secures Funding

LONDON (Alliance News) - Destiny Pharma PLC said Thursday it had been jointly granted funding with the University of Southampton to examine the use of its technology to eradicate clinical caused a

Read more
25 Oct 2018 11:23

Destiny Pharma Hires Creabilis's Shaun Claydon As New Finance Head

LONDON (Alliance News) - Destiny Pharma PLC said on Thursday it has appointed Shaun Claydon as its new finance chief after the departure of Chief Financial Officer Simon Sacerdoti.Claydon,

Read more
19 Oct 2018 14:54

Destiny Pharma helps with new bioindustry association videos

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.

Read more
26 Sep 2018 12:39

Destiny Pharma Loss More Than Doubles On Administrative Expenses

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday reported a substantial widening of its loss in the first half of the year due to administrative expenses.The clinical stage company

Read more
6 Sep 2018 13:24

Destiny Pharma Chairman Nigel Rudd To Step Down In December

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that Chairman Nigel Rudd stepped down from the company in December after eight years.Non-Executive Director Nick Rodgers will Rudd

Read more
6 Sep 2018 10:32

Chairman of Destiny calling time after 15 years with pharma firm

(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.

Read more
26 Jul 2018 13:49

Destiny Pharma Receives Positive Results From Skin Irritation Study

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that it received positive data from the Phase I of its XF-73 skin irritation study.The clinical stage biotechnology company said is

Read more
21 Jun 2018 10:25

Destiny Pharma Appoints SEHTA Chairman Nick Rodgers As Non-Executive

LONDON (Alliance News) - Anti-microbial resistance-focused biotechnology developer Destiny Pharma PLC said Thursday it has appointed Nick Rodgers as an independent non-executive director with is a

Read more
30 May 2018 13:00

Destiny Pharma Creates Independent Scientific Advisory Board

LONDON (Alliance News) - Destiny Pharma PLC said Wednesday it has formed a scientific advisory board to provide "expert, independent analysis" of the company's research and clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.